This site uses Google Analytics for tracking site performance.
We've revealed critical insights across the healthcare landscape with innovative methodologies, novel technologies and world-class expertise.
“Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer” (Carrato et al); Future Oncology, 2021
“First- and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe“ (Taieb et al); ESMO Open, 2020
Baseline characteristics for metastatic pancreatic adenocarcinoma (mPAC) patients receiving first-line (1L) FOLFIRINOX, gemcitabine+nab-paclitaxel (GEM-NAB) or gemcitabine-monotherapy (GEM) treatment (tx) – (ESMO GI; Sociedad Española de Oncología Médica, SEOM 2018) – Patient Chart Audit
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review; (Buske et al. The Lancet Hematology, July 2018
Genactis is part of